Recce Pharmaceuticals Ltd. (R9Q) Income Statement
Recce Pharmaceuticals Ltd. Income Statement
Last quarter (Q4 2026), Recce Pharmaceuticals Ltd.'s total revenue was $0.00, a decrease of 100.00% from the same quarter last year. In Q4, Recce Pharmaceuticals Ltd.'s net income was $1.60M. See Recce Pharmaceuticals Ltd.’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Jun 26 | Jun 25 | Jun 24 | Jun 23 | Jun 22 |
|---|---|---|---|---|---|
| $ 0.00 | $ 7.51M | $ 5.03M | $ 4.37M | $ 3.08M | |
| $ -356.40K | $ -2.94M | $ -2.19M | $ 4.15M | $ 2.90M | |
| $ 22.81M | $ 19.94M | $ 21.68M | $ 17.11M | $ 13.96M | |
| Depreciation and Amortization | $ 356.40K | $ 356.16K | $ 366.77K | $ 217.16K | $ 187.67K |
| $ -22.81M | $ -20.05M | $ -21.35M | $ -16.99M | $ -13.87M | |
| $ -23.16M | $ -22.88M | $ -22.05M | $ -17.33M | $ -14.15M | |
| $ -677.39K | $ 1.45M | $ -516.49K | $ -63.06K | $ 79.07K | |
| $ -23.84M | $ -21.43M | $ -22.57M | $ -17.39M | $ -14.07M | |
| $ -14.96M | $ -21.43M | $ -17.66M | $ -13.08M | $ -10.99M | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.05 | $ -0.09 | $ -0.10 | $ -0.07 | $ -0.06 |
| Diluted EPS | $ -0.05 | $ -0.09 | $ -0.10 | $ -0.07 | $ -0.06 |
| Weighted Average Shares Outstanding | 289.15M | 236.98M | 177.10M | 175.71M | 175.87M |
| Weighted Average Shares Outstanding (Diluted) | 289.15M | 236.98M | 177.10M | 175.71M | 175.87M |
Currency in AUD